
Blood test may detect ovarian cancer two years earlier
Peer reviewed by Natalie HealeyLast updated by Milly EvansLast updated 23 Aug 2019
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
Researchers have developed a screening test which could detect a type of ovarian cancer up to two years earlier than current tests.
The study, published in Nature, analysed blood samples from 80 people over seven years.
According to lead author of the study, Dr Bobby Graham from Queen's University Belfast, they found biomarkers for ovarian cancer in the blood and these were used to develop a blood test to detect it.
"Firstly, we discovered that the presence of the biomarker panel will enable us to detect ovarian cancer. We then developed a screening test to detect this biomarker panel, making this a relatively simple diagnostic test."
This new test identifies the likelihood of epithelial ovarian cancer (EOC) up to two years earlier than the currently available tests.
"The results of this study are encouraging," said Graham. "We now want to focus on testing it in a wider sample set so that we can use the data to advocate for an ovarian cancer screening programme."
Ovarian cancer is the sixth most common cancer in women in the UK, more common than cervical cancer. Around 7,000 women are diagnosed with it each year, the majority of cases occurring in women over 50. Sadly, most cases are diagnosed at a later stage when survival rates are lower as symptoms such as bloating often do not occur until after the cancer has grown or spread. There is currently no ovarian cancer screening programme available in the UK.
The study was jointly funded by Cancer Research UK and The Eve Appeal. Dr Rachel Shaw, research information officer at Cancer Research UK, called the results "encouraging". "Developing simple tests like these that could help detect the disease sooner is essential," she said.
"Sadly, so many women are diagnosed late, to devastating effect. We are hopeful the outcomes of this project will have a positive effect on women in the future," said CEO of The Eve Appeal, Athena Lamnisos.
This study was published in Nature.
Patient picks for Gynaecological cancer

Cancer
Do lesbian and bisexual women still need smear tests?
Cervical cancer is the most common cancer in women aged 35 and under, with around 3,000 women diagnosed each year in the UK. Despite this, just 72 per cent of eligible women in England attend cervical screening (or smear) tests, which can help to detect abnormal cells early, and prevent around 75 per cent of cervical cancers from developing. In the LGBT+ community however, the figures are much lower still. According to Lawrie Roberts, Macmillan LGBT and Cancer Programme Co-ordinator at the LGBT Foundation, around half (51 per cent) of eligible women who have sex with women have never attended a smear test.
by Sarah Graham

Cancer
What are the common myths and facts about cervical screening?
Cervical screening is an essential way to reduce the risk of cervical cancer, but research shows many women and people with cervixes are delaying or not attending their screenings. Feeling embarrassed is a common obstacle, as is misinformation about what smear tests involve. So what are the common myths surrounding cervical screening - and what are the facts?
by Lydia Smith
Continue reading below
Article history
The information on this page is peer reviewed by qualified clinicians.
23 Aug 2019 | Latest version

Ask, share, connect.
Browse discussions, ask questions, and share experiences across hundreds of health topics.

Feeling unwell?
Assess your symptoms online for free